Key Insights

Highlights

Success Rate

56% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 65/100

Termination Rate

14.8%

4 terminated out of 27 trials

Success Rate

55.6%

-31.0% vs benchmark

Late-Stage Pipeline

37%

10 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed with results

Key Signals

56% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (6)
P 1 (1)
P 2 (5)
P 3 (9)
P 4 (1)

Trial Status

Unknown8
Recruiting8
Completed5
Terminated4
Active Not Recruiting1
Withdrawn1

Trial Success Rate

55.6%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT04564157Phase 3Active Not Recruiting

New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy

NCT07562659Phase 2Recruiting

Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer

NCT07521397Completed

Pooled Analysis of Patients With Early-stage Breast Cancer Treated With Adjuvant Dose-dense Sequential Chemotherapy: a Hellenic Cooperative Oncology Group (HeCOG) Study.

NCT07136077Phase 2Recruiting

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

NCT03748485Not ApplicableRecruiting

Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis

NCT07366528Phase 3Recruiting

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

NCT06949033Phase 3Recruiting

Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06925243Phase 3Recruiting

Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

NCT03228043Not ApplicableWithdrawn

Apatinib for Resectable Colorectal Cancer

NCT06671431Completed

Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma

NCT06389552RecruitingPrimary

Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

NCT03858166Phase 4TerminatedPrimary

Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer

NCT05735145Phase 3Recruiting

Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer

NCT03079427Phase 2Completed

Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma

NCT05613465Not ApplicableUnknown

Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /Placebo

NCT03748680Phase 2Unknown

IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer

NCT04070313Phase 2Terminated

A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan

NCT03702868Terminated

Relationship Between Gut Microbiome and Adjuvant Chemotherapy in Patients With Early Breast Cancer

NCT04303429Phase 3Unknown

Adjuvant Chemotherapy in High Risk Stage II Colon Cancer

NCT03199989Phase 3UnknownPrimary

Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)

Scroll to load more

Research Network

Activity Timeline